Puberty Blocker Trial Reapproved: What Kent Families Need to Know

The Trial Back in the Spotlight

A controversial UK clinical trial into the use of puberty-suppressing hormones in children with gender incongruence has been reapproved by regulators, according to a post by the British Medical Journal.

The trial had previously faced scrutiny over its design. Regulators have now signed off on a revised protocol, allowing the research to move forward.

What Puberty Blockers Actually Are

Puberty-suppressing hormones — commonly called puberty blockers — are medicines that pause the physical changes of puberty. In plain terms, they delay the development of things like body hair, breast growth, and voice changes.

They have been used for decades to treat children who go through puberty too early — a condition known as precocious puberty. But their use in children with gender incongruence, where a person’s sense of their own gender doesn’t match the sex they were registered at birth, has been far more contested.

The NHS in England suspended routine prescribing of puberty blockers for gender dysphoria in young people following the publication of the Cass Review in April 2024. That independent review, led by Dr Hilary Cass, found the evidence base for their use was “remarkably weak.” The medicines regulator, the MHRA, then restricted their use outside of clinical trials.

Why the Trial Was Controversial

The original trial design attracted criticism from both sides of the debate. Some clinicians and researchers argued the protocol lacked sufficient safeguards or long-term follow-up measures. Others felt the research was needed precisely because the evidence gap was so large.

It’s that evidence gap — not ideology — that regulators say the trial is designed to close.

The reapproval suggests those concerns have been addressed to the satisfaction of the relevant regulatory bodies, though critics and supporters of the research are likely to continue watching its progress closely.

The Wider Picture

Gender-related healthcare for children and young people has become one of the most debated areas of NHS policy The closure of the Gender Identity Development Service at the Tavistock Centre in London, and the subsequent rollout of new regional hubs, reshaped how young people in England access this kind of care.

Kent and Medway residents seeking support for children or young people with gender incongruence can access services through their GP, who can refer to the appropriate NHS pathway.

—

Key Takeaways

• A UK clinical trial into puberty-suppressing hormones in children with gender incongruence has been reapproved after its protocol was revised
• The NHS in England currently restricts puberty blocker prescribing for gender dysphoria outside of approved clinical trials, following the Cass Review
• Regulators have not yet published full details of what changes were made to the trial protocol

What This Means for Kent Residents

Kent families with children or young people who have gender incongruence should speak to their GP as the first point of contact — GPs can advise on current NHS referral pathways and what services are available locally. The NHS does not currently prescribe puberty blockers for gender dysphoria outside of clinical research settings, so families should be cautious about information circulating online that may not reflect current guidance. For general health queries, call NHS 111, or in an emergency dial 999. The Samaritans are available around the clock on 116 123 for anyone struggling emotionally.